AIMS: To identify molecular characteristics to hepatitis C virus (HCV)-associated diffuse large B-cell lymphoma (DLBCL) through a comprehensive miRNAs expression profiling. METHODS: In this study, miRNA profiles were obtained from 37 patients with DLBCLs and 60 patients with reactive lymph nodes, equally distributed according to HCV presence. Germinal centres, from reactive lymph nodes were used as controls. Clinical features at presentation were available for all patients. RESULTS: A set of 52 miRNAs define a signature for HCV-associated DLBCL. Importantly, decreased expression of miR-138-5p and increased expression of miR-147a, miR-147b and miR-511-5p in HCV DLBCL was found to be a poor prognostic factor for HCV-positive DLBCL patients. CONCLUSIONS: These data reveal molecular differences in diffuse DLBCL patients according to HCV presence, potentially useful as novel prognostic or therapeutic biomarkers. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions

MicroRNA as potential biomarker in HCV-associated diffuse large B-cell lymphoma / C. Augello, U. Gianelli, F. Savi, A. Moro, E. Bonoldi, M. Gambacorta, V. Vaira, L. Baldini, S. Bosari. - In: JOURNAL OF CLINICAL PATHOLOGY. - ISSN 0021-9746. - 67:8(2014 Aug), pp. 697-701. [10.1136/jclinpath-2014-202352]

MicroRNA as potential biomarker in HCV-associated diffuse large B-cell lymphoma

C. Augello;U. Gianelli;V. Vaira;L. Baldini;S. Bosari
2014-08

Abstract

AIMS: To identify molecular characteristics to hepatitis C virus (HCV)-associated diffuse large B-cell lymphoma (DLBCL) through a comprehensive miRNAs expression profiling. METHODS: In this study, miRNA profiles were obtained from 37 patients with DLBCLs and 60 patients with reactive lymph nodes, equally distributed according to HCV presence. Germinal centres, from reactive lymph nodes were used as controls. Clinical features at presentation were available for all patients. RESULTS: A set of 52 miRNAs define a signature for HCV-associated DLBCL. Importantly, decreased expression of miR-138-5p and increased expression of miR-147a, miR-147b and miR-511-5p in HCV DLBCL was found to be a poor prognostic factor for HCV-positive DLBCL patients. CONCLUSIONS: These data reveal molecular differences in diffuse DLBCL patients according to HCV presence, potentially useful as novel prognostic or therapeutic biomarkers. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Settore MED/15 - Malattie del Sangue
JOURNAL OF CLINICAL PATHOLOGY
Article (author)
File in questo prodotto:
File Dimensione Formato  
8.pdf

non disponibili

Tipologia: Publisher's version/PDF
Dimensione 4.74 MB
Formato Adobe PDF
4.74 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/245610
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 25
social impact